Cerebral aspergillosis: An emerging opportunistic infection in patients receiving ibrutinib for chronic lymphocytic leukemia?

E Gaye, A Le Bot, JP Talarmin… - Médecine et …, 2018 - univ-rennes.hal.science
Ibrutinib is a novel oral covalent inhibitor of Bruton's tyrosine kinase (BTK). It has been
approved for the treatment of relapsing chronic lymphocytic leukemia (CLL), or CLL with …
被引用次数：13 相关文章

Cerebral aspergillosis: An emerging opportunistic infection in patients receiving ibrutinib for chronic lymphocytic leukemia?

E Gaye, A Le Bot, JP Talarmin, R Le Calloch… - Médecine et Maladies …, 2018 - hal.science
Ibrutinib is a novel oral covalent inhibitor of Bruton's tyrosine kinase (BTK). It has been
approved for the treatment of relapsing chronic lymphocytic leukemia (CLL), or CLL with …

Cerebral aspergillosis: an emerging opportunistic infection in patients receiving ibrutinib for chronic lymphocytic leukemia?

E Gaye, A Bot, JP Talarmin, R Calloch, S Belaz… - 2018 - cabidigitallibrary.org
This paper report 2 cases of cerebral asergillosis in chronic lymphocytic leukemia (CLL)
treated with ibrutinib. First case was a 75-year-old man and the second patient was a 65 …

Cerebral aspergillosis: An emerging opportunistic infection in patients receiving ibrutinib for chronic lymphocytic leukemia?

E Gaye, A Le Bot, JP Talarmin… - Medecine et …, 2018 - pubmed.ncbi.nlm.nih.gov
Cerebral aspergillosis: An emerging opportunistic infection in patients receiving ibrutinib for
chronic lymphocytic leukemia? Cerebral aspergillosis: An emerging opportunistic infection …

[引用][C] Cerebral aspergillosis: An emerging opportunistic infection in patients receiving ibrutinib for chronic lymphocytic leukemia?

E Gaye, A Le Bot, JP Talarmin… - Medecine et Maladies …, 2018 - europepmc.org
Cerebral aspergillosis: An emerging opportunistic infection in patients receiving ibrutinib for
chronic lymphocytic leukemia? - Abstract - Europe PMC Sign in | Create an account https://orcid.org …